Gavreto is a cancer medicine for treating adults with advanced non-small cell lung cancer caused by changes in a gene called RET (known as RET fusion-positive NSCLC) and who have not been treated with a RET inhibitor. Gavreto contains the active substance pralsetinib.
Therapeutic Indication
### Therapeutic indication Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.
Therapeutic Area (MeSH)
N/AATC Code
L01EX23
ATC Item
pralsetinib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| pralsetinib | N/A | 普拉替尼 |
EMA Name
Gavreto
Medicine Name
Gavreto
Aliases
N/ANo risk management plan link.
